<DOC>
	<DOCNO>NCT00795210</DOCNO>
	<brief_summary>The purpose study examine short-term effect two different dos growth hormone , compare treatment growth hormone release hormone , brain 's secretion growth hormone body 's glucose metabolism . We hypothesize growth hormone administration alter body 's endogenous pulsatile growth hormone secretion high dose growth hormone may decrease insulin sensitivity . We hypothesize growth hormone release hormone augment endogenous GH pulsatility neutral insulin sensitivity .</brief_summary>
	<brief_title>Effects Short-term Growth Hormone HIV-infected Patients</brief_title>
	<detailed_description>The primary objective study determine differential effect growth hormone release hormone ( GHRH ) vs. low dose physiologic growth hormone ( GH ) vs. high dose GH treatment withdrawal endogenous overnight growth hormone secretion pulsatility , well insulin-stimulated glucose uptake . Subjects HIV-infection randomize receive one three treatment : GHRH 2mg/day , growth hormone 6mcg/kg/day ( physiologic `` low '' dose ) , growth hormone 2mg/day ( `` high '' dose ) 2 week . At baseline two week treatment , assess overnight growth hormone frequent sample well insulin stimulate glucose uptake clamp . Subjects stop treatment return identical assessment 2 week withdrawal period .</detailed_description>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Growth Hormone-Releasing Hormone</mesh_term>
	<criteria>previously diagnose HIV infection Stable antiretroviral regimen least 12 week prior enrollment Waist circumference &gt; /= 95cm waisttohip ratio &gt; /= 0.94 male waist circumference &gt; /=94cm WHR &gt; /= 0.88 female , occur context treatment HIV disease Subjective evidence least one follow change , occur treatment HIV disease : increase abdominal girth , relative loss fat extremity , relative loss fat face Use antidiabetic agent , Megace , testosterone , steroid use within 6 month study Use GH Growth hormone release factor within six month start study Change lipid lower antihypertensive regimen within 3 month screen Fasting blood sugar &gt; 126mg/dL , SGOT &gt; 2.5 time ULN , Hgb &lt; 12.0 g/dL , creatinine &gt; 1.4 mg/dL , FSH &gt; 20 IU/L woman , CD4 count &lt; 200 Carpal tunnel syndrome Severe chronic illness active malignancy history pituitary malignancy history colon cancer For men , history prostate cancer evidence prostate malignancy PSA &gt; 5ng/mL Prior history hypopituitarism , head irradiation , condition know affect GH axis positive betaHCG ( woman ) Oral contraceptive , depo provera , combine progesteroneestrogen injection , transdermal contraceptive patch , estrogen progestin coat IUD 's within 6 month study weight &lt; 110 pound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>HIV lipodystrophy</keyword>
	<keyword>growth hormone</keyword>
	<keyword>growth hormone release hormone</keyword>
</DOC>